Industry groups petition the FDA over off-label rule
UPDATE: The FDA announced March 17 that it would delay the rule until March 19, 2018.
Industry groups are taking aim at a rule created by the Food and Drug Administration that could restrict drugmakers' truthful and non-misleading promotion of its drugs - commonly referred to as off-label promotion - by expanding the evidence the agency can use to assert that a drug has been misbranded.
The FDA filed the final rule in the Federal Register on January 9. A citizen petition was filed by...